pp-005 Tablets 25mg, 100mg, 150mg
Dossier type
CTD
Dossier status
Under development
Country of origin
China
GMP approvals
China
Comments
"Phase 3 oral GnRH antagonist, in the same drug class as Elagolix. Indication: Prevention of premature ovulation during controlled ovarian hyperstimulation in assisted reproductive technology (monotherapy). Monotherapy"
Manufacturer #17216
Global developer of innovative drugs in oncology, metabolic, autoimmune, and cardiovascular diseases, with 14 in-house products and multiple partnerships. Over 5,000 R&D staff across global centers and strong IP, clinical pipeline, and high-standard manufacturing.
Manufacturer usually replies in 41 days